Close menu




VALNEVA SE EO -_15

Photo credits: pixabay.com

Commented by Nico Popp on October 19th, 2022 | 13:52 CEST

Biotech funds looking over their shoulders: Bavarian Nordic, Cardiol Therapeutics, Valneva

  • Biotechnology

A recent study by Accenture shows that consumers are not willing to reduce their spending on health and wellness - even if things are not going well economically. Despite uncertainties, respondents see spending in the areas of "health" and "fitness" as "essential." Those who pay for these areas are also likely to want to exhaust all options when it comes to health insurance benefits, such as medications and vaccines. Informed patients and consumers put pressure on their doctors when new therapies are available. Health insurers, who are also in competition with each other, are taking this into account. We highlight three biotech stocks and do the investment check.

Read

Commented by André Will-Laudien on October 12th, 2022 | 11:31 CEST

Biotech in the scope: BioNTech, XPhyto Therapeutics, MorphoSys, Valneva - The cards are reshuffled!

  • Biotechnology
  • Pharma

Cancer remains one of the greatest afflictions of our time, along with cardiovascular disease. Despite the tremendous progress already made in the fight against cancer, there remains an unmet medical need for many types of cancer. Cancer was responsible for nearly 10 million deaths worldwide in 2020. Other diseases, such as Alzheimer's and Parkinson's, also continue to be the focus of research. How is the biotech industry faring after the pandemic and during the stock market storm?

Read

Commented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST

BioNTech, XPhyto, Valneva - It is over!

  • Biotechnology
  • Covid19
  • Cannabis

In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.

Read

Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST

Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?

  • Biotechnology
  • Cancer
  • vaccine

Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.

Read

Commented by Juliane Zielonka on August 18th, 2022 | 13:50 CEST

Apple, Tocvan Ventures, Valneva - More returns through innovation or risk hedging?

  • Mining
  • Gold
  • Innovations
  • Pharma

Innovations are hailed as market drivers. The more innovative a company is, the more likely it is to stay ahead of the competition. But this requires loyal customers who also support these innovations. And Apple has just such a customer base, setting a good example that loyalty must be rewarded for innovation. In contrast, pharmaceutical company Valneva has the challenge of exposure to different development cycles in the healthcare market. If only because of the duration of clinical studies, which rightly have to go well before a new product comes onto the market. This time, nature lovers could benefit. Those who find all this too volatile and unpredictable should once again turn to commodities as a hedge. With Tocvan Ventures, a candidate is in the running that looks very closely at optimizing the costs of its operations - to the benefit of investors.

Read

Commented by Armin Schulz on August 9th, 2022 | 13:45 CEST

BioNTech, Defence Therapeutics, Valneva - Will biotech stocks continue to rally in the fall?

  • Biotechnology
  • Covid19
  • Cancer

The NASDAQ Biotechnology Index formed a double bottom in mid-June and has since rallied, breaking the downtrend. However, there is still over 32% potential to the past highs. The highs are due in part to the sales from the Corona Crisis, but even though currently the issue is not as present despite higher case numbers, that could change in the fall. The new Protection Against Infection Act provides for mask-wearing and further vaccinations. The profits from these sales are often invested in the development of new therapies, such as cancer research. These areas hold a lot of potential for rising share prices. We take a closer look at three biotech companies.

Read

Commented by Carsten Mainitz on July 28th, 2022 | 13:35 CEST

BioNTech, Defence Therapeutics, Valneva - Will the fall bring a new boost?

  • Biotechnology
  • Covid19
  • vaccine

Officials expect the Corona pandemic to intensify sharply in the fall. Already, the number of cases is rising, as is the number of hospitalizations. To be better equipped against the currently prevalent Omicron variant, BioNTech/Pfizer have specifically adapted the Comirnaty vaccine to it. Valneva's recently approved vaccine also provides good protection against Omicron through a broader immune response to its inactivated vaccine. Also involved in vaccine development is the Canadian company Defence Therapeutics. It is currently attracting attention with its cancer-fighting developments and could become a real gem.

Read

Commented by Nico Popp on July 21st, 2022 | 11:24 CEST

Time is of the essence! Bavarian Nordic, XPhyto, Valneva

  • Biotechnology
  • Covid19

Resourceful investors always bet on corresponding stocks when new pathogens or disease patterns become known. BioNTech was one of the early movers in the case of COVID-19, but so were several other stocks that are now unknown again. Even for monkeypox, there have long been stocks that have profited - for example, the share of smallpox vaccine manufacturer Bavarian Nordic which recently rose sharply. We explain the hype around pharmaceutical stocks and outline where there could still be potential now.

Read

Commented by André Will-Laudien on July 18th, 2022 | 15:04 CEST

Fall is coming: BioNTech, Defence Therapeutics, CureVac, Valneva - Which biotech stock will surge again?

  • Biotechnology
  • Covid19

The summer of rising incidences is making its way, but the public has already shelved the pandemic measures and hospitals are filling up again. Even if no one wants to talk about it anymore, the fourth wave is coming! Worldwide, the race for suitable vaccines or treatment methods continues. Medicine is still relatively helpless as far as treating severe cases is concerned, and the subject of post-COVID is considered completely unexplored. We take another critical look at the landscape of biotech stocks.

Read

Commented by Fabian Lorenz on July 7th, 2022 | 14:33 CEST

A big surprise at BioNTech, and what are Valneva and NervGen doing?

  • Biotechnology
  • research

Surprise at BioNTech: competitor CureVac sues the Mainz-based biotech company for alleged patent infringements. Specifically, the lawsuit concerns BioNTech's Corona vaccine, which is based on mRNA technology. CureVac founder Ingmar Hoerr, in turn, is considered the discoverer of this new vaccination technology. However, CureVac failed with the development of its own Corona vaccine. Valneva also had no luck with its Corona vaccine, but it seems to have an attractive product pipeline. Nevertheless, the euphoria over the entry of the US pharmaceutical group Pfizer has faded. The situation at NervGen is different: according to experts, NervGen could achieve its greatest success in decades with NVG-291 in the fight against Alzheimer's disease. Tomorrow, a capital increase is to be completed, and the share price will likely regain momentum.

Read